$15,000 per signed retainer. That’s the ceiling on the most expensive lead in mass tort. And firms pay it without hesitation.
Because the case on the other side of that $15,000 settles for $1 million to $2.5 million. The average trial verdict is $20.7 million. The largest verdict in 2025 was $1.5 billion.
Mesothelioma isn’t a hot tort. It’s the tort. The one that’s been running for 40 years and shows no sign of stopping. Every other mass tort measures itself against it.
Why It Never Dies
Twenty-seven million Americans were exposed to asbestos at work between 1940 and 1979. Mesothelioma has a latency period of 20 to 50 years. That math is simple and permanent.
The CDC tracks 2,669 cases in the most recent reporting year. The American Cancer Society estimates roughly 3,000. Eighty-one percent are pleural (lung lining). Seventy-six percent are male. Average age at diagnosis: 72.
The US finally banned asbestos in 2024. That affects future exposure. It does nothing for the millions already exposed decades ago.
New cases will keep appearing through the 2040s. No settlement resolves that. No legislation stops it. The diagnoses were set in motion 40 to 60 years ago.
The Economics
No other mass tort comes close.
Average settlement: $1 million to $2 million. Average trial verdict: $20.7 million. Dollars per resolved claim rose 12% in 2024 versus 2023. That’s the seventh consecutive year of increases. A 191% cumulative rise since 2017.
On a $10,000 CPA, a $1.5 million settlement produces a 150:1 return. Even at $15,000 per signed retainer against a $1 million settlement, that’s 67:1. No other tort in any category produces those multiples at that scale.
The buy-in is enormous. The return is more enormous.
$30 Billion in Trust Funds
Sixty-plus asbestos trust funds hold over $30 billion for claimants. Created when asbestos companies filed Chapter 11 bankruptcy, these trusts pay claims independently of active litigation.
A mesothelioma patient can pursue both tracks simultaneously. File claims against trust funds for bankrupt companies. Sue surviving defendants in court.
Most patients were exposed to products from multiple companies. One case recovered $2.4 million from trusts alone, then additional millions from lawsuit settlements. Individual trust payouts range from $8,800 to $350,000. Across multiple trusts, patients access $300,000 to $400,000 on average.
The trusts are durable. The money is there. The pipeline of eligible claimants stretches decades.
The Verdict History
Mesothelioma verdicts don’t just win. They rewrite records.
December 2025: $1.5 billion against Johnson & Johnson. Peritoneal mesothelioma from talc-contaminated Baby Powder. Baltimore jury. The largest mesothelioma verdict in history.
October 2025: $966 million against J&J. Los Angeles jury. $950 million in punitive damages.
September 2025: $34.2 million. Portland jury. Shipyard worker exposed to asbestos gaskets.
March 2025: $18 million. Florida jury. Secondary exposure from a father’s auto repair shop.
Only 5% of mesothelioma cases reach a jury. Ninety-five percent settle. The verdicts matter because they set the floor for settlement negotiations.
And talc is supercharging everything. Talc allegations now appear in over 40% of all mesothelioma filings, up from less than 5% in 2015. Ninety percent of talc asbestos trials have been decided for the plaintiff. J&J as a defendant adds a deep-pocketed consumer products company to the traditional industrial manufacturer lineup.
Who’s Spending
Mesothelioma advertising is a four-firm game on TV. Sokolove Law, Maune Raichle Hartley French & Mudd, Pulaski & Middleman, and Weitz & Luxenberg account for over 50% of all broadcast spend.
Whitehardt removed mesothelioma from their monthly hot tort rankings entirely. Their explanation: “This tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game.”
Simmons Hanly Conroy has recovered $10.7 billion. Over 100 attorneys. A dedicated bankruptcy trust department. Sokolove Law has recovered $5.3 billion and effectively operates as Simmons’ lead generation arm.
Weitz & Luxenberg increased filings 69% in 2025 versus 2024. Meirowitz & Wasserberg up 86%. The established players are scaling, not retreating.
The barrier to entry keeps the economics clean. You can’t dabble in mesothelioma advertising. A $5,000 minimum CPA with 3,000 annual diagnoses across 131 million US households means only firms with serious budgets and deep litigation infrastructure can play.
The Channel Mix
Broadcast dominates at roughly 55%. The “if you or a loved one was diagnosed with mesothelioma” format has been running for two decades because it works. The core demographic (72-year-old male veterans) still watches linear TV.
Search captures about 30%. “Mesothelioma” is the single most expensive keyword in Google’s advertising ecosystem. CPCs exceed $300 per click in active jurisdictions. Plaintiff firms spend over $50 million annually on Google Ads alone.
Social is minimal at 10%. The demographic doesn’t convert on Instagram.
CTV sits at 5% and represents the gap. The mesothelioma audience is aging into streaming. Cord-cutting among 65-85 year olds is accelerating. But the established firms built their pipelines on broadcast and haven’t shifted yet.
Here’s the CTV reality for mesothelioma: with 3,000 diagnoses per year across 131 million households, even the best behavioral targeting delivers 99%+ non-qualifying impressions. CTV’s advantage for this tort isn’t precision targeting. It’s attribution. The household-to-call closed loop tells you exactly which ad produced which call, something broadcast can’t do.
No MDL
Mesothelioma has no multi-district litigation. Cases are filed individually in state courts across the country. That’s fundamentally different from every other major mass tort.
Individual filing means no single judge controls settlement dynamics. No centralized bellwether caps values. Plaintiff firms venue-shop for favorable jurisdictions.
Top jurisdictions in 2025: Madison County and St. Clair County in Illinois. Philadelphia (up 57%). New York (up 24%). Alameda County, California.
Between 3,500 and 4,100 asbestos lawsuits are filed annually. KCIC data shows filings up 4% through mid-2025, with 1,106 mesothelioma-specific filings in the first seven months.
Qualification
Diagnosis is the threshold. Pleural mesothelioma (81% of cases), peritoneal (11%), pericardial (less than 1%), or testicular (less than 1%).
Then: exposure history. Occupational is the strongest. Construction, shipyard work, insulation, automotive repair, Navy service, industrial manufacturing. The plaintiff must document specific asbestos-containing products and identify manufacturers.
Secondary exposure qualifies. Family members exposed through contaminated work clothing. The March 2025 Florida verdict ($18 million) was secondary exposure from laundering a father’s work clothes.
Consumer product exposure is the growth category. Talc-based baby powder and cosmetics contaminated with asbestos. Now alleged in 40%+ of all filings.
Work history documentation is everything. Per mesothelioma attorney Samuel Meirowitz: “The most important part of the process is taking down an occupational history and asking all the right questions in terms of what work was done, and what products were used.”
Veterans represent one-third of all cases. Five-year survival rate: 15%. Typical lawsuit timeline: six to 12 months from filing to settlement.
The Play
Mesothelioma isn’t a tort you enter casually. Three realities define the opportunity.
First, the buy-in is real. $5,000 to $15,000 per signed retainer. Minimum $50,000 per month in advertising to generate meaningful volume. The firms winning have seven-figure annual acquisition budgets.
Second, CTV is the underexploited channel. The audience is aging into streaming. Attribution gives you closed-loop tracking that broadcast never offered. The incumbents are slow to move because their broadcast pipelines still work. That’s the window.
Third, trust fund expertise is the differentiator. Firms that know how to file across 60+ trusts, recover $300,000-$400,000 per case in trust payouts on top of litigation settlements, and manage the bankruptcy claim process have a structural advantage that advertising alone can’t replicate.
This tort will outlast everyone reading this. The pipeline is locked in through the 2040s. The economics have only gotten better for seven consecutive years. The question isn’t whether mesothelioma is worth advertising. It’s whether you have the infrastructure to convert a $15,000 lead into a $2 million case.
Most firms don’t. The ones that do have been running for decades. And they aren’t slowing down.
References
- CDC U.S. Cancer Statistics. Malignant Mesothelioma Incidence and Mortality, 2003-2022
- NERA Economic Consulting. Asbestos Litigation Update, June 2025
- KCIC. Asbestos Litigation: 2025 Mid-Year Review and DRI Annual Update
- Whitehardt Mass Tort Report: Hot Tort Rankings and Lead Economics, Q1 2026
- Simmons Hanly Conroy. Asbestos Trust Fund Claims and Recoveries